ANAB

60.55

14.61% 7.72

Vorhandelsmarkt: 59.05 -1.50 -2.48%

Anaptysbio Inc (ANAB)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$52.83

Offen:

$56.08

24-Stunden-Volumen:

1.10M

Relative Volume:

2.43

Marktkapitalisierung:

$1.68B

Einnahmen:

$169.47M

Nettoeinkommen (Verlust:

$-84.63M

KGV:

-21.48

EPS:

-2.8189

Netto-Cashflow:

$-145.42M

1W Leistung:

+9.87%

1M Leistung:

+25.16%

6M Leistung:

+187.10%

1J Leistung:

+297.05%

1-Tages-Spanne:

$54.17

$62.69

1-Wochen-Bereich:

$52.68

$62.69

52-Wochen-Spanne:

$15.12

$62.69

Anaptysbio Inc Stock (ANAB) Company Profile

Firmenname

Anaptysbio Inc

Sektor

Healthcare (1106)

Branche

Biotechnology (621)

Telefon

858-362-6295

Adresse

10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA

Mitarbeiter

136

Twitter

@anaptysbio

Nächster Verdiensttermin

2024-11-08

Neueste SEC-Einreichungen

ANAB's Discussions on Twitter

Compare ANAB vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ANAB Anaptysbio Inc	60.55	1.46B	169.47M	-84.63M	-145.42M	-2.8189
VRTX Vertex Pharmaceuticals Inc	477.89	120.48B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	787.50	81.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	749.56	46.33B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	327.30	42.26B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	299.02	32.87B	5.36B	287.73M	924.18M	2.5229

Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-07	Fortgesetzt	UBS	Buy
2025-10-13	Eingeleitet	Barclays	Overweight
2025-06-04	Hochstufung	H.C. Wainwright	Neutral → Buy
2025-02-04	Eingeleitet	Wolfe Research	Outperform
2024-12-11	Herabstufung	H.C. Wainwright	Buy → Neutral
2024-12-02	Herabstufung	BTIG Research	Buy → Neutral
2024-07-22	Eingeleitet	H.C. Wainwright	Buy
2024-07-19	Hochstufung	JP Morgan	Neutral → Overweight
2024-04-16	Eingeleitet	Leerink Partners	Outperform
2024-04-11	Eingeleitet	Wells Fargo	Overweight
2024-03-12	Hochstufung	Wedbush	Neutral → Outperform
2024-02-26	Eingeleitet	BTIG Research	Buy
2024-02-21	Eingeleitet	Stifel	Buy
2024-02-16	Eingeleitet	Piper Sandler	Overweight
2023-05-22	Hochstufung	JP Morgan	Underweight → Neutral
2023-05-18	Eingeleitet	TD Cowen	Outperform
2023-01-06	Herabstufung	Raymond James	Outperform → Mkt Perform
2022-11-01	Hochstufung	Guggenheim	Neutral → Buy
2022-09-19	Fortgesetzt	H.C. Wainwright	Buy
2022-09-13	Herabstufung	Truist	Buy → Hold
2022-09-01	Eingeleitet	Raymond James	Outperform
2022-03-22	Herabstufung	Guggenheim	Buy → Neutral
2021-06-22	Eingeleitet	H.C. Wainwright	Buy
2021-05-21	Eingeleitet	UBS	Neutral
2021-03-16	Hochstufung	Truist	Hold → Buy
2021-03-09	Herabstufung	Wedbush	Outperform → Neutral
2021-03-08	Herabstufung	JP Morgan	Overweight → Underweight
2021-02-11	Hochstufung	JP Morgan	Underweight → Overweight
2020-10-27	Hochstufung	Wedbush	Neutral → Outperform
2020-10-14	Hochstufung	Guggenheim	Neutral → Buy
2019-11-08	Herabstufung	JP Morgan	Overweight → Underweight
2019-11-08	Herabstufung	Jefferies	Buy → Hold
2019-11-08	Herabstufung	SunTrust	Buy → Hold
2019-11-08	Herabstufung	Wedbush	Outperform → Neutral
2019-06-21	Herabstufung	Credit Suisse	Outperform → Neutral
2019-06-21	Herabstufung	Stifel	Buy → Hold
2018-12-20	Eingeleitet	H.C. Wainwright	Buy
2018-11-21	Eingeleitet	JP Morgan	Overweight
2018-07-19	Eingeleitet	Credit Suisse	Outperform
2018-04-04	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2018-03-27	Bestätigt	Stifel	Buy
2018-03-06	Bestätigt	Stifel	Buy
2018-02-15	Bestätigt	SunTrust	Buy
2018-01-23	Bestätigt	Credit Suisse	Outperform
2017-11-15	Eingeleitet	SunTrust	Buy
2017-11-09	Eingeleitet	Jefferies	Buy
2017-10-11	Bestätigt	RBC Capital Mkts	Outperform
2017-09-15	Eingeleitet	RBC Capital Mkts	Outperform

Alle ansehen

Anaptysbio Inc Aktie (ANAB) Neueste Nachrichten

07:36 AM

Stifel Raises Price Target for AnaptysBio (ANAB) to $85, Reaffir - GuruFocus

07:36 AM

01:10 AM

AnaptysBio stock hits 52-week high at 57.86 USD By Investing.com - Investing.com Canada

01:10 AM

Mar 04, 2026

AnaptysBio (ANAB) Q4 Profit Of US$49.6 Million Tests Longstanding Loss-Making Narrative - simplywall.st

Mar 04, 2026

AnaptysBio Says R&D Spinout May Launch By April - Citeline News & Insights

Mar 04, 2026

AnaptysBio Details Plan to Split Into RoyaltyCo and Biopharma at TD Cowen Healthcare Conference - Yahoo Finance

Mar 04, 2026

AnaptysBio stock hits 52-week high at 57.86 USD - Investing.com

Mar 04, 2026

AnaptysBio Hits New 52-Week High After Analyst Upgrade - National Today

Mar 04, 2026

AnaptysBio (NASDAQ:ANAB) Hits New 52-Week High Following Analyst Upgrade - MarketBeat

Mar 04, 2026

ANAB: Barclays Raises Price Target to $79, Maintains Overweight Rating | ANAB Stock News - GuruFocus

Mar 04, 2026

AnaptysBio (NASDAQ:ANAB) Price Target Raised to $79.00 - MarketBeat

Mar 04, 2026

AnaptysBio (NASDAQ:ANAB) Price Target Raised to $66.00 at HC Wainwright - MarketBeat

Mar 04, 2026

H.C. Wainwright raises AnaptysBio stock price target to $66 By Investing.com - Investing.com Canada

Mar 04, 2026

Wedbush Raises Price Target on AnaptysBio to $60 From $50, Keeps Outperform Rating - marketscreener.com

Mar 04, 2026

AnaptysBio Swings To Q4 Profit, Narrows FY25 Loss; Spin-Off Of Biopharma Operations In Q2 2026 - Nasdaq

Mar 04, 2026

HC Wainwright & Co. Raises Price Target and Maintains Buy Rating for ANAB | ANAB Stock News - GuruFocus

Mar 04, 2026

GSK's Biopharma Collaborations Highlighted in AnaptysBio Spin-Of - GuruFocus

Mar 04, 2026

Beyond the Balance Sheet: What SWOT Reveals About AnaptysBio Inc (ANAB) - GuruFocus

Mar 04, 2026

Mar 03, 2026

Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results - Bitget

Mar 03, 2026